AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NRx Pharmaceuticals Reports Q2 Earnings, Updates on Ketamir-2 Trial
ByAinvest
Friday, Aug 22, 2025 2:18 pm ET1min read
NRx Pharmaceuticals reported a Q2 loss per share of (98c), compared to (75c) YoY. The company has $2.9M in cash and believes it will support operations into 2026 and reach expected regulatory inflection points. CEO Jonathan Javitts highlighted progress with the company's lead programs and the attraction of a group of fundamental biotechnology investors. MIRA Pharmaceuticals completed the Single Ascending Dose portion of its Phase 1 clinical trial for oral Ketamir-2, demonstrating a favorable safety and tolerability profile.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet